2017 Volume 33 Issue 4 Pages 533-536
The aim of this paragraph is to introduce recent advances in the studies of gliomatosis cerebri, intravascular lymphoma, lymphomatoid granulomatosis and neurosarcoidosis to neurological clinicians based on reports published in 2015. Any four are very rare, and their neurological manifestations are non–specific, hence they are difficult to diagnose, in early phases.
Regarding gliomatosis cerebri, younger patients showed good performance scores before therapy, underwent combined chemotherapy and had good survival outcomes. Diagnosing intravascular lymphoma requires considerable labor because it does not form a mass. In 2015, cases where successfully detected by endoscopic biopsy and nasal biopsy, were reported. Both biopsies are minimally invasive and can be recommended hereafter. A rare case of a patient with primary cerebral lymphomatoid granulomatosis which caused various neurological symptoms and progressed to methotrexate–associated lymphoproliferative disease, suggests that clonal analysis of the specimens are of importance to plan a treatment strategy. In diagnosing neurosarcoidosis, analysis of angiotensin converting enzyme from serum or cerebrospinal fluid did not show accurate results even though they were much anticipated. In the treatment of neurosarcoidosis, immunosuppressannts, monoclonal antibodies and intravenous immunoglobulin therapy were proposed as part of a combination therapy or second line therapy.
